跳转至内容
Merck
所有图片(1)

主要文件

SML0241

Sigma-Aldrich

Ganirelix acetate salt

≥95% (HPLC), lyophilized powder, GnRH antagonist

别名:

Antagon, N-Acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-[bis(ethylamino)methylene]-D-lysyl-L-leucyl-N6-[bis(ethylamino)methylene]-L-lysyl-L-prolyl-D-alaninamide diacetate, Orgalutran

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C80H113ClN18O13 · 2C2H4O2
CAS号:
129311-55-3
分子量:
1690.42
分類程式碼代碼:
51111800
NACRES:
NA.77

产品名称

Ganirelix acetate salt, ≥95% (HPLC)

品質等級

100

化驗

≥95% (HPLC)

形狀

lyophilized powder

顏色

white

儲存溫度

−20°C

InChI

1S/C80H113ClN18O13.2C2H4O2/c1-9-84-79(85-10-2)88-38-17-15-24-60(70(104)94-62(41-49(5)6)71(105)93-61(25-16-18-39-89-80(86-11-3)87-12-4)78(112)99-40-20-26-68(99)77(111)90-50(7)69(82)103)92-73(107)64(44-53-30-35-59(102)36-31-53)97-76(110)67(48-100)98-75(109)66(46-55-21-19-37-83-47-55)96-74(108)65(43-52-28-33-58(81)34-29-52)95-72(106)63(91-51(8)101)45-54-27-32-56-22-13-14-23-57(56)42-54;2*1-2(3)4/h13-14,19,21-23,27-37,42,47,49-50,60-68,100,102H,9-12,15-18,20,24-26,38-41,43-46,48H2,1-8H3,(H2,82,103)(H,90,111)(H,91,101)(H,92,107)(H,93,105)(H,94,104)(H,95,106)(H,96,108)(H,97,110)(H,98,109)(H2,84,85,88)(H2,86,87,89);2*1H3,(H,3,4)/t50-,60-,61+,62+,63?,64-,65+,66+,67-,68?;;/m1../s1

InChI 密鑰

OVBICQMTCPFEBS-HYVLHXRFSA-N

生化／生理作用

Ganirelix is a decapeptide GnRH antagonist. Ganirelix acts by blocking the action of GnRH upon the pituitary, thus rapidly suppressing the production and action of LH and FSH.

象形圖

Exclamation mark
GHS07

訊號詞

Warning

危險聲明

H315,H319,H335

危險分類

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

標靶器官

Respiratory system

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

从最新的版本中选择一种：

分析证书(COA)

Lot/Batch Number
022M4736V

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Nicole Kummer et al.
Fertility and sterility, 96(1), 63-68 (2011-05-14)
To determine factors predicting cycle success after in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) in high-risk patients undergoing controlled ovarian stimulation with a gonadotropin-releasing hormone (GnRH) antagonist protocol with a GnRH agonist to induce oocyte maturation. Retrospective cohort
Luteal phase GnRHa trigger in random start fertility preservation cycles.
Enis Ozkaya et al.
Journal of assisted reproduction and genetics, 29(6), 503-505 (2012-04-12)
George Griesinger et al.
Reproductive biomedicine online, 23(4), 457-465 (2011-08-17)
The association between endogenous LH concentrations during ovarian stimulation in a gonadotrophin-releasing hormone (GnRH) antagonist protocol and pregnancy likelihood was examined in a large combined analysis of individualized patient data obtained after treatment with recombinant FSH and a GnRH antagonist
Johannes D Veldhuis et al.
American journal of physiology. Endocrinology and metabolism, 302(1), E117-E122 (2011-10-06)
Direct sampling of the human spermatic veins has disclosed concomitant LH and testosterone (T) pulses, suggesting pulsatile LH concentration-dependent stimulation of T secretion. However, studies to date have examined this hypothesis using only pharmacological stimulation with hCG. The present study
Heraldo Mendes Garmes et al.
Fertility and sterility, 97(1), 231-234 (2011-11-29)
To describe the management of a patient with a pituitary adenoma secreting follicle-stimulating hormone (FSH) associated with ovarian hyperstimulation who was treated with a gonadotropin-releasing hormone (GnRH) antagonist. Case report. University teaching hospital. A woman of reproductive age with secondary
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门